Gene-Therapeutic Strategies Targeting Angiogenesis in Peripheral Artery Disease

The World Health Organization announced that cardiovascular disease is the number one cause of death globally, representing 31% of all global deaths. Coronary artery disease (CAD) affects approximately 5% of the US population aged 40 years and older. With an age-adjusted prevalence of approximately...

Full description

Bibliographic Details
Main Authors: Fumihiro Sanada, Yoshiaki Taniyama, Jun Muratsu, Rei Otsu, Hideo Shimizu, Hiromi Rakugi, Ryuichi Morishita
Format: Article
Language:English
Published: MDPI AG 2018-03-01
Series:Medicines
Subjects:
Online Access:http://www.mdpi.com/2305-6320/5/2/31
_version_ 1819082114033778688
author Fumihiro Sanada
Yoshiaki Taniyama
Jun Muratsu
Rei Otsu
Hideo Shimizu
Hiromi Rakugi
Ryuichi Morishita
author_facet Fumihiro Sanada
Yoshiaki Taniyama
Jun Muratsu
Rei Otsu
Hideo Shimizu
Hiromi Rakugi
Ryuichi Morishita
author_sort Fumihiro Sanada
collection DOAJ
description The World Health Organization announced that cardiovascular disease is the number one cause of death globally, representing 31% of all global deaths. Coronary artery disease (CAD) affects approximately 5% of the US population aged 40 years and older. With an age-adjusted prevalence of approximately 12%, peripheral artery disease (PAD) affects at least 8 to 12 million Americans. Both CAD and PAD are caused by mainly atherosclerosis, the hardening and narrowing of arteries over the years by lipid deposition in the vascular bed. Despite the significant advances in interventions for revascularization and intensive medical care, patients with CAD or PAD who undergo percutaneous transluminal angioplasty have a persistent high rate of myocardial infarction, amputation, and death. Therefore, new therapeutic strategies are urgently needed for these patients. To overcome this unmet need, therapeutic angiogenesis using angiogenic growth factors has evolved in an attempt to stimulate the growth of new vasculature to compensate for tissue ischemia. After nearly 20 years of investigation, there is growing evidence of successful or unsuccessful gene therapy for ischemic heart and limb disease. This review will discuss basic and clinical data of therapeutic angiogenesis studies employing angiogenic growth factors for PAD patients and will draw conclusions on the basis of our current understanding of the biological processes of new vascularization.
first_indexed 2024-12-21T20:11:31Z
format Article
id doaj.art-bb61525c2ec3497980676ea0842d4954
institution Directory Open Access Journal
issn 2305-6320
language English
last_indexed 2024-12-21T20:11:31Z
publishDate 2018-03-01
publisher MDPI AG
record_format Article
series Medicines
spelling doaj.art-bb61525c2ec3497980676ea0842d49542022-12-21T18:51:45ZengMDPI AGMedicines2305-63202018-03-01523110.3390/medicines5020031medicines5020031Gene-Therapeutic Strategies Targeting Angiogenesis in Peripheral Artery DiseaseFumihiro Sanada0Yoshiaki Taniyama1Jun Muratsu2Rei Otsu3Hideo Shimizu4Hiromi Rakugi5Ryuichi Morishita6Department of Clinical Gene Therapy, Osaka University Graduate School of Medicine, Suita, Osaka 565-0871, JapanDepartment of Clinical Gene Therapy, Osaka University Graduate School of Medicine, Suita, Osaka 565-0871, JapanDepartment of Clinical Gene Therapy, Osaka University Graduate School of Medicine, Suita, Osaka 565-0871, JapanDepartment of Clinical Gene Therapy, Osaka University Graduate School of Medicine, Suita, Osaka 565-0871, JapanDepartment of Clinical Gene Therapy, Osaka University Graduate School of Medicine, Suita, Osaka 565-0871, JapanDepartment of Geriatric and General Medicine, Osaka University Graduate School of Medicine, Suita, Osaka 565-0871, JapanDepartment of Clinical Gene Therapy, Osaka University Graduate School of Medicine, Suita, Osaka 565-0871, JapanThe World Health Organization announced that cardiovascular disease is the number one cause of death globally, representing 31% of all global deaths. Coronary artery disease (CAD) affects approximately 5% of the US population aged 40 years and older. With an age-adjusted prevalence of approximately 12%, peripheral artery disease (PAD) affects at least 8 to 12 million Americans. Both CAD and PAD are caused by mainly atherosclerosis, the hardening and narrowing of arteries over the years by lipid deposition in the vascular bed. Despite the significant advances in interventions for revascularization and intensive medical care, patients with CAD or PAD who undergo percutaneous transluminal angioplasty have a persistent high rate of myocardial infarction, amputation, and death. Therefore, new therapeutic strategies are urgently needed for these patients. To overcome this unmet need, therapeutic angiogenesis using angiogenic growth factors has evolved in an attempt to stimulate the growth of new vasculature to compensate for tissue ischemia. After nearly 20 years of investigation, there is growing evidence of successful or unsuccessful gene therapy for ischemic heart and limb disease. This review will discuss basic and clinical data of therapeutic angiogenesis studies employing angiogenic growth factors for PAD patients and will draw conclusions on the basis of our current understanding of the biological processes of new vascularization.http://www.mdpi.com/2305-6320/5/2/31angiogenesisgene therapyhepatocyte growth factor
spellingShingle Fumihiro Sanada
Yoshiaki Taniyama
Jun Muratsu
Rei Otsu
Hideo Shimizu
Hiromi Rakugi
Ryuichi Morishita
Gene-Therapeutic Strategies Targeting Angiogenesis in Peripheral Artery Disease
Medicines
angiogenesis
gene therapy
hepatocyte growth factor
title Gene-Therapeutic Strategies Targeting Angiogenesis in Peripheral Artery Disease
title_full Gene-Therapeutic Strategies Targeting Angiogenesis in Peripheral Artery Disease
title_fullStr Gene-Therapeutic Strategies Targeting Angiogenesis in Peripheral Artery Disease
title_full_unstemmed Gene-Therapeutic Strategies Targeting Angiogenesis in Peripheral Artery Disease
title_short Gene-Therapeutic Strategies Targeting Angiogenesis in Peripheral Artery Disease
title_sort gene therapeutic strategies targeting angiogenesis in peripheral artery disease
topic angiogenesis
gene therapy
hepatocyte growth factor
url http://www.mdpi.com/2305-6320/5/2/31
work_keys_str_mv AT fumihirosanada genetherapeuticstrategiestargetingangiogenesisinperipheralarterydisease
AT yoshiakitaniyama genetherapeuticstrategiestargetingangiogenesisinperipheralarterydisease
AT junmuratsu genetherapeuticstrategiestargetingangiogenesisinperipheralarterydisease
AT reiotsu genetherapeuticstrategiestargetingangiogenesisinperipheralarterydisease
AT hideoshimizu genetherapeuticstrategiestargetingangiogenesisinperipheralarterydisease
AT hiromirakugi genetherapeuticstrategiestargetingangiogenesisinperipheralarterydisease
AT ryuichimorishita genetherapeuticstrategiestargetingangiogenesisinperipheralarterydisease